These include Caspase-6 (CASP6) whose proteolytically processed form has been shown to increase in correlation with amyloid beta pathologies in Alzheimer’s disease patients [59]. This evidence concerns the gene CASP6 and early-onset autosomal dominant Alzheimer disease.